|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2011. View
Article : Google Scholar
|
|
2
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roy BC, Kohno T, Iwakawa R, Moriguchi T,
Kiyono T, Morishita K, Sanchez-Cespedes M, Akiyama T and Yokota J:
Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of
human lung cancer cells. Lung Cancer. 70:136–145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rhodes LV, Tate CR, Hoang VT, Burks HE,
Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D,
et al: Regulation of triple-negative breast cancer cell metastasis
by the tumor-suppressor liver kinase B1. Oncogenesis. 4:e1682015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo Z, Zang M and Guo W: AMPK as a
metabolic tumor suppressor: Control of metabolism and cell growth.
Future Oncol. 6:457–470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sánchez-Tilló E, Siles L, de Barrios O,
Cuatrecasas M, Vaquero EC, Castells A and Postigo A: Expanding
roles of ZEB factors in tumorigenesis and tumor progression. Am J
Cancer Res. 1:897–912. 2011.PubMed/NCBI
|
|
9
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lehmann W, Mossmann D, Kleemann J, Mock K,
Meisinger C, Brummer T, Herr R, Brabletz S, Stemmler MP and
Brabletz T: ZEB1 turns into a transcriptional activator by
interacting with YAP1 in aggressive cancer types. Nat Commun.
7:104982016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Edgar BA: From cell structure to
transcription: Hippo forges a new path. Cell. 124:267–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thongon N, Castiglioni I, Zucal C, Latorre
E, D'Agostino V, Bauer I, Pancher M, Ballestrero A, Feldmann G,
Nencioni A, et al: The GSK3β inhibitor BIS I reverts YAP-dependent
EMT signature in PDAC cell lines by decreasing SMADs expression
level. Oncotarget. 7:26551–26566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shao DD, Xue W, Krall EB, Bhutkar A,
Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et
al: KRAS and YAP1 converge to regulate EMT and tumor survival.
Cell. 158:171–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mohseni M, Sun J, Lau A, Curtis S,
Goldsmith J, Fox VL, Wei C, Frazier M, Samson O, Wong KK, et al: A
genetic screen identifies an LKB1-MARK signalling axis controlling
the Hippo-YAP pathway. Nat Cell Biol. 16:108–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu Q, Li J and Sun S, Chen X, Zhang H, Li
B and Sun S: YAP/TAZ-mediated activation of serine metabolism and
methylation regulation is critical for LKB1-deficient breast cancer
progression. Biosci Rep. 37:BSR201710722017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang W, Gao Y, Li F, Tong X, Ren Y, Han
X, Yao S, Long F, Yang Z, Fan H, et al: YAP promotes malignant
progression of Lkb1-deficient lung adenocarcinoma through
downstream regulation of survivin. Cancer Res. 75:4450–4457. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao Y, Zhang W, Han X, Li F, Wang X, Wang
R, Fang Z, Tong X, Yao S, Li F, et al: YAP inhibits squamous
transdifferentiation of Lkb1-deficient lung adenocarcinoma through
ZEB2-dependent DNp63 repression. Nat Commun. 5:46292014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Steinhardt AA, Gayyed MF, Klein AP, Dong
J, Maitra A, Pan D, Montgomery EA and Anders RA: Expression of
Yes-associated protein in common solid tumors. Hum Pathol.
39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fisher ML, Grun D, Adhikary G, Xu W and
Eckert RL: Inhibition of YAP function overcomes BRAF inhibitor
resistance in melanoma cancer stem cells. Oncotarget.
8:110257–110272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barbier-Torres L, Delgado TC,
García-Rodríguez JL, Zubiete-Franco I, Fernández-Ramos D, Buqué X,
Cano A, Gutiérrez-de Juan V, Fernández-Domínguez I, Lopitz-Otsoa F,
et al: Stabilization of LKB1 and Akt by neddylation regulates
energy metabolism in liver cancer. Oncotarget. 6:2509–2523. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Y, Lu X, Huang L, Wang W, Jiang G,
Dean KC, Clem B, Telang S, Jenson AB, Cuatrecasas M, et al:
Different thresholds of ZEB1 are required for Ras-mediated tumour
initiation and metastasis. Nat Commun. 5:56602014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bronsert P, Kohler I, Timme S, Kiefer S,
Werner M, Schilling O, Vashist Y, Makowiec F, Brabletz T, Hopt UT,
et al: Prognostic significance of Zinc finger E-box binding
homeobox 1 (ZEB1) expression in cancer cells and cancer-associated
fibroblasts in pancreatic head cancer. Surgery. 156:97–108. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spaderna S, Schmalhofer O, Wahlbuhl M,
Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A,
et al: The transcriptional repressor ZEB1 promotes metastasis and
loss of cell polarity in cancer. Cancer Res. 68:537–544. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zender L, Spector MS, Xue W, Flemming P,
Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et
al: Identification and validation of oncogenes in liver cancer
using an integrative oncogenomic approach. Cell. 125:1253–1267.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo J, Wu Y, Yang L, Du J, Gong K, Chen W,
Dai J, Li X and Xi S: Repression of YAP by NCTD disrupts NSCLC
progression. Oncotarget. 8:2307–2319. 2017.PubMed/NCBI
|
